{"id":390756,"date":"2017-12-24T00:00:00","date_gmt":"2017-12-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfon0002-2017-biopharma-hepatocellular-carcinoma-niche-rare-disease-landscape-forecast-us-eu5-2017\/"},"modified":"2026-03-31T10:49:01","modified_gmt":"2026-03-31T10:49:01","slug":"nrlfon0002-2017-biopharma-hepatocellular-carcinoma-niche-rare-disease-landscape-forecast-us-eu5-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfon0002-2017-biopharma-hepatocellular-carcinoma-niche-rare-disease-landscape-forecast-us-eu5-2017\/","title":{"rendered":"Hepatocellular Carcinoma | Niche &#038; Rare Disease Landscape &#038; Forecast | US\/EU5 | 2017"},"content":{"rendered":"<p>Hepatocellular carcinoma\u00a0is a primary malignancy of the liver; the majority of cases arise from underlying liver cirrhosis. Treatment of hepatocellular carcinoma incorporates a variety of multimodal approaches; advanced (metastatic) disease is treated with palliative intent. Bayer HealthCare\/Amgen\/Onyx\u2019s Nexavar is the only agent approved for first-line advanced hepatocellular carcinoma, and\u00a0Bayer HealthCare\u2019s Stivarga and Bristol-Myers Squibb\u2019s Opdivo (United States only) are\u00a0approved as second-line treatments. The late-phase therapy pipeline for hepatocellular carcinoma is focused on the advanced setting\u00a0and encompasses a diverse range of mechanisms of action (<abbr title=\"mechanism of action\">MOA<\/abbr>s).\u00a0Because\u00a0the hepatocellular carcinoma\u00a0therapy market is largely untapped, developers of efficacious drugs can\u00a0reap high commercial rewards.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>How large is the treatable hepatocellular carcinoma population, and how will drug-treatment rates change over time?<\/li>\n<li>How is hepatocellular carcinoma currently treated, and what are interviewed experts\u2019 insights on current treatment options? What clinical needs remain unfulfilled?<\/li>\n<li>Who are the key players in the late-phase development pipeline for hepatocellular carcinoma? Which agents or drug classes are most promising? What therapies of note are progressing in earlier phases?<\/li>\n<li>Which emerging therapies do we forecast to enter the hepatocellular carcinoma market during the forecast period? What sales\/uptake could they secure in this niche oncology indication?<\/li>\n<\/ul>\n<p><strong>Scope: <\/strong><\/p>\n<p><b>Market covered: <\/b>United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p><b>Primary research: <\/b>Eight country-specific interviews with thought leaders (medical oncologists and hepatologists).<\/p>\n<p><b>Epidemiology: <\/b> Diagnosed incident cases of hepatocellular carcinoma: early-stage hepatocellular carcinoma, intermediate-stage hepatocellular carcinoma, and advanced-stage hepatocellular carcinoma.<\/p>\n<p><b>Population segments in market forecast: <\/b>Early-stage hepatocellular carcinoma, intermediate-stage hepatocellular carcinoma, advanced first-line hepatocellular carcinoma, and advanced second-line hepatocellular carcinoma.<\/p>\n<p><b>Emerging therapies: <\/b>Phase III: 10 drugs; Phase II: 22 drugs; coverage of select Phase I and preclinical products.<\/p>\n<p><strong>Product Description:<\/strong> Niche &#038; Rare Disease Landscape &#038; Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390756","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hepatocellular-carcinoma","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390756\/revisions"}],"predecessor-version":[{"id":576760,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390756\/revisions\/576760"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}